Literature DB >> 20192945

The neurotrophic factor pleiotrophin modulates amphetamine-seeking behaviour and amphetamine-induced neurotoxic effects: evidence from pleiotrophin knockout mice.

Esther Gramage1, Alessia Putelli, Maria J Polanco, Carmen González-Martín, Laura Ezquerra, Luis F Alguacil, Pablo Pérez-Pinera, Thomas F Deuel, Gonzalo Herradón.   

Abstract

Pleiotrophin (PTN), a neurotrophic factor with important roles in survival and differentiation of dopaminergic neurons, is up-regulated in the nucleus accumbens after amphetamine administration suggesting that PTN could modulate amphetamine-induced pharmacological or neuroadaptative effects. To test this hypothesis, we have studied the effects of amphetamine administration in PTN genetically deficient (PTN -/-) and wild type (WT, +/+) mice. In conditioning studies, we found that amphetamine induces conditioned place preference in both PTN -/- and WT (+/+) mice. When these mice were re-evaluated after a 5-day period without amphetamine administration, we found that WT (+/+) mice did not exhibit amphetamine-seeking behaviour, whereas, PTN -/- mice still showed a robust drug-seeking behaviour. In immunohystochemistry studies, we found that amphetamine (10 mg/kg, four times, every 2 hours) causes a significant increase of glial fibrillary acidic protein positive cells in the striatum of amphetamine-treated PTN -/- mice compared with WT mice 4 days after last administration of the drug, suggesting an enhanced amphetamine-induced astrocytosis in the absence of endogenous PTN. Interestingly, we found in concomitant in vitro studies that PTN (3 µM) limits amphetamine (1 mM)-induced loss of viability of PC12 cell cultures, effect that could be related to the ability of PTN to induce the phosphorylation of Akt and ERK1/2. To test this possibility, we used specific Akt and ERK1/2 inhibitors uncovering for the first time that PTN-induced protective effects against amphetamine-induced toxicity in PC12 cells are mediated by the ERK1/2 signalling pathway. The data suggest an important role of PTN to limit amphetamine-induced neurotoxic and rewarding effects.
© 2010 The Authors, Addiction Biology © 2010 Society for the Study of Addiction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20192945     DOI: 10.1111/j.1369-1600.2009.00202.x

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  15 in total

1.  Development of inhibitors of receptor protein tyrosine phosphatase β/ζ (PTPRZ1) as candidates for CNS disorders.

Authors:  Miryam Pastor; Rosalía Fernández-Calle; Bruno Di Geronimo; Marta Vicente-Rodríguez; José María Zapico; Esther Gramage; Claire Coderch; Carmen Pérez-García; Amy W Lasek; Leonor Puchades-Carrasco; Antonio Pineda-Lucena; Beatriz de Pascual-Teresa; Gonzalo Herradón; Ana Ramos
Journal:  Eur J Med Chem       Date:  2017-11-28       Impact factor: 6.514

Review 2.  Pleiotrophin: Activity and mechanism.

Authors:  Xu Wang
Journal:  Adv Clin Chem       Date:  2020-03-12       Impact factor: 5.394

Review 3.  Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives.

Authors:  G Herradón; C Pérez-García
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

4.  Pharmacological inhibition of Receptor Protein Tyrosine Phosphatase β/ζ (PTPRZ1) modulates behavioral responses to ethanol.

Authors:  Rosalía Fernández-Calle; Marta Vicente-Rodríguez; Miryam Pastor; Esther Gramage; Bruno Di Geronimo; José María Zapico; Claire Coderch; Carmen Pérez-García; Amy W Lasek; Beatriz de Pascual-Teresa; Ana Ramos; Gonzalo Herradón
Journal:  Neuropharmacology       Date:  2018-05-09       Impact factor: 5.250

5.  Acute Morphine, Chronic Morphine, and Morphine Withdrawal Differently Affect Pleiotrophin, Midkine, and Receptor Protein Tyrosine Phosphatase β/ζ Regulation in the Ventral Tegmental Area.

Authors:  Daniel García-Pérez; M Luisa Laorden; M Victoria Milanés
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

6.  Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes.

Authors:  Richard Sherva; Congcong Zhu; Leah Wetherill; Howard J Edenberg; Emma Johnson; Louisa Degenhardt; Arpana Agrawal; Nicholas G Martin; Elliot Nelson; Henry R Kranzler; Joel Gelernter; Lindsay A Farrer
Journal:  Explor Med       Date:  2021-02-28

7.  Pleiotrophin expression and role in physiological angiogenesis in vivo: potential involvement of nucleolin.

Authors:  Marina Koutsioumpa; Georgia Drosou; Constantinos Mikelis; Katerina Theochari; Dionussios Vourtsis; Panagiotis Katsoris; Efstathia Giannopoulou; Jose Courty; Christos Petrou; Vassiliki Magafa; Paul Cordopatis; Evangelia Papadimitriou
Journal:  Vasc Cell       Date:  2012-03-16

8.  ALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers.

Authors:  Anton Wellstein
Journal:  Front Oncol       Date:  2012-12-19       Impact factor: 6.244

Review 9.  An animal model of differential genetic risk for methamphetamine intake.

Authors:  Tamara J Phillips; Shkelzen Shabani
Journal:  Front Neurosci       Date:  2015-09-23       Impact factor: 4.677

10.  Behavioral and neuroanatomical abnormalities in pleiotrophin knockout mice.

Authors:  Jason W Krellman; Henry H Ruiz; Veronica A Marciano; Bracha Mondrow; Susan D Croll
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.